Cosmo Pharmaceuticals NV COPN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €72.10
- Day Range
- €71.50–72.50
- 52-Week Range
- €33.70–76.00
- Bid/Ask
- €70.00 / €72.00
- Market Cap
- €1.15 Bil
- Volume/Avg
- 4,709 / 18,772
Key Statistics
- Price/Earnings (Normalized)
- 69.17
- Price/Sales
- 11.93
- Dividend Yield (Trailing)
- 1.43%
- Dividend Yield (Forward)
- 2.70%
- Total Yield
- 2.94%
Company Profile
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Stock Style Box
- Small Core
- Total Number of Employees
- 319
- Website
- https://www.cosmopharma.com
Comparables
Valuation
|
Metric
|
COPN
|
INVA
|
THQM
|
|---|---|---|---|
Price/Earnings (Normalized) | 69.17 | 9.30 | 517.10 |
Price/Book Value | 3.15 | 1.43 | 14.43 |
Price/Sales | 11.93 | 4.27 | 31.80 |
Price/Cash Flow | 30.38 | 7.99 | 475.92 |
Price/Earnings
COPN
INVA
THQM
Financial Strength
|
Metric
|
COPN
|
INVA
|
THQM
|
|---|---|---|---|
Quick Ratio | 1.35 | 7.28 | 4.00 |
Current Ratio | 1.42 | 9.03 | 5.28 |
Interest Coverage | 2.75 | 10.31 | 6.04 |
Quick Ratio
COPN
INVA
THQM
Profitability
|
Metric
|
COPN
|
INVA
|
THQM
|
|---|---|---|---|
Return on Assets (Normalized) | 2.29% | 14.79% | 2.40% |
Return on Equity (Normalized) | 4.19% | 29.29% | 2.78% |
Return on Invested Capital (Normalized) | 3.44% | 16.71% | 2.60% |
Return on Assets
COPN
INVA
THQM
Drug Manufacturers - General Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
LLY
| Eli Lilly and Co | Ykkhqswnb | Kcwt | $697.4 Bil | |
JNJ
| Johnson & Johnson | Cxqlyzxk | Rlwry | $353.8 Bil | |
MRK
| Merck & Co Inc | Znpdkslk | Wcf | $332.3 Bil | |
ABBV
| AbbVie Inc | Gzkhbzhtz | Dwvx | $282.6 Bil | |
AZN
| AstraZeneca PLC ADR | Lkyrnxtsz | Lxrcj | $232.3 Bil | |
NVS
| Novartis AG ADR | Twclrggt | Rdgz | $200.1 Bil | |
RHHBY
| Roche Holding AG ADR | Yvnsrvjjls | Rpf | $195.3 Bil | |
AMGN
| Amgen Inc | Srgkryyfz | Nyn | $144.5 Bil | |
PFE
| Pfizer Inc | Rylbttxs | Dtxc | $143.8 Bil | |
SNY
| Sanofi SA ADR | Qxnfjzyx | Mqn | $122.2 Bil |